XPhyto Therapeutics will operate the site located at the University of Alberta
XPhyto Therapeutics has announced that its pharmaceutical-grade extraction and processing laboratory is now complete and is ready for commissioning and operations. The facility is located at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, in Edmonton, Canada.
The lab is supervised by Professor Raimar Loebenberg, founder and director of the Drug Development and Innovation Centre at the University of Alberta, and director of XPhyto.
XPhyto’s current cannabis R&D focus at the lab is on topical treatments for inflammatory dermatology indications and oral and ingestible treatments for pain management and sleep disorders.
The company is also working on solubility solutions for both decarboxylated and acid forms of cannabinoids.
We believe the next wave of cannabis investment opportunities will be focused on formulation, drug delivery, precision dosing, clinical validation, and European and emerging markets
XPhyto said operations at the lab will run in parallel to German operations, via its 100% owned Vektor Pharma TF GmbH, which are focused on novel thin film (oral and transdermal) drug delivery methods and innovative cannabis-based products.
Hugh Rogers, CEO of XPhyto, commented: “We believe the next wave of cannabis investment opportunities will be focused on formulation, drug delivery, precision dosing, clinical validation, and European and emerging markets."
For Rogers, XPhyto’s pharma-grade extraction lab coming online in Canada, plus the cannabis import licences and EU GMP lab in Germany, strengthens the company's position to take advantage of emerging trends in the rapidly evolving cannabis industry.
"XPhyto has engaged in discussions with multiple potential third-party collaborators seeking cannabis-related contract research and development services from the lab and the XPhyto team. This presents a new business opportunity for the company," the company said in a statement.